FDA Approves Imvexxy for Treatment of Post-Menopausal Pain


Jul 10, 2018

FDA Approves Imvexxy for Treatment of Post-Menopausal PainStarting this month, post-menopausal ladies may have a brand new remedy choice for painful intercourse.  

In May 2018, the U.S. Food and Drug Administration (FDA) accepted Imvexxy, an estradiol vaginal insert for ladies with moderate-to-severe sexual ache. According to a press assertion, TherapeuticsMD, the drug’s producer, expects Imvexxy to be obtainable in July.

Sexual ache is a standard drawback after menopause, when a lady’s estrogen ranges drop significantly. Estrogen is essential for protecting vaginal tissue healthy and versatile. When ranges decline, the vagina can shorten and slender, with the partitions changing into dry and brittle. Women might discover that their vagina is much less lubricated throughout intercourse. Together, these signs can result in uncomfortable friction, tearing, and bleeding throughout vaginal intercourse.

The medical time period for this case is vaginal and vulvar atrophy (VVA). An estimated 50% of postmenopausal ladies expertise it to some extent. Unfortunately, VVA doesn’t enhance by itself.

Next »
(web page 1 of 2)


Source link

Leave a Comment

Your email address will not be published. Required fields are marked *